RedDrop Dx is a medical device company focused on solving the blood-collection bottleneck in telehealth and decentralized diagnostics. Its FDA-cleared flagship product, the RedDrop ONE lancet, lets patients collect up to one milliliter of capillary blood into a standardized, automation-compatible tube without a phlebotomist. Because the tube is compatible with high-throughput laboratory automation, partner labs can process remote samples without redesigning workflows or sacrificing quality. The company collaborates with clinical laboratories, telehealth providers, life-science firms, and decentralized clinical-trial organizations to enable population-scale testing and chronic-disease monitoring. Proceeds from its latest financing will be used to expand manufacturing capacity, accelerate commercial partnerships, and advance platform development for decentralized clinical trials and telehealth diagnostics. Headquartered in Fort Collins, Colorado, RedDrop Dx aims to become the industry standard infrastructure for scalable at-home blood collection. The company’s financial position has been strengthened by an oversubscribed $5 million seed round led by institutional and strategic investors.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

Dec 2025